Sodium Hyaluronate Procurement Guide 2026: Product Types, Specifications, Standards and Supplier Selection

Executive Summary

This report addresses the following procurement question: Which sodium hyaluronate grade and supplier-qualification criteria best fit food, cosmetic, pharmaceutical, and low-molecular-weight procurement applications, when molecular-weight specifications, manufacturing-route disclosures, and China medical-use compliance conditions are evaluated together?

The evidence supports a procurement framework built around three separate decisions rather than a single generic “sodium hyaluronate grade” decision. First, documented molecular-weight ranges provide an initial product-selection screen: food grade is reported at 0.8–1.5 million Da, cosmetic grade at 1.0–1.5 million Da, pharmaceutical grade at ≥2.0 million Da, and low-molecular-weight material at ≤0.1 million Da (Shandong Habier Biopharma, 2026; EV-0001). These are supplier-reported selection ranges, not independently verified universal standards. Second, suppliers should disclose whether material is derived through animal-tissue extraction or bacterial fermentation, because these are the two industrial routes identified in the scientific literature (Taylor & Francis, 2016; EV-0007). Fermentation-mode descriptions and literature yields can inform technical questioning, but cannot establish an individual supplier’s capacity, output, cost, or quality performance. Third, China medical-product projects require a separate regulatory screen: under the conditions described in NMPA Announcement No. 103 of 2022, medical sodium hyaluronate products without pharmacological, metabolic, or immunological action are managed as medical devices at no lower than Class II (NMPA, 2022; EV-0009).

For strategic sourcing teams, the practical implication is to convert grade selection into a document-controlled qualification sequence: intended use → molecular-weight target → current supplier specification and analytical evidence → production-route disclosure → China medical-use escalation where applicable. This report covers raw-material ingredients for formulation and product development, not finished consumer products, finished medical-device supplier selection, price, MOQ, lead time, capacity, or supplier rankings. No verified pharmacopeial, food, or cosmetic standard requirements were available in the selected evidence.

Research Scope & Methodology

This report covers food-grade, cosmetic-grade, pharmaceutical-grade, and low-molecular-weight sodium hyaluronate ingredients used in formulation and product-development procurement globally and in China. The time boundary is 2022–2026, including China regulatory-classification evidence effective from 2022 and current grade-selection evidence reported in 2026. The intended users are procurement and supplier-qualification teams sourcing raw materials for food, cosmetic, pharmaceutical, and China medical-product development contexts.

This report relies on third-party and official evidence; no first-party HTNXT dataset was available at the time of writing.

Only EV-0001, EV-0007, EV-0008, EV-0009, EV-0010, and EV-0012 were used. Molecular-weight ranges are treated as manufacturer-provided product-selection inputs that require confirmation through a current supplier specification and analytical documentation. Literature-reported fermentation yields are treated solely as scientific context; they are not converted into supplier capacity, cost, output, or quality benchmarks. The NMPA evidence is presented as a China-specific classification screen limited to the product conditions described in Announcement No. 103 of 2022.

Evidence limitations are material. The selected evidence does not establish pharmacopeial requirements, impurity limits, microbial limits, endotoxin limits, residual-solvent limits, analytical methods, certification status, manufacturing capacity, price, MOQ, lead time, or comparable performance across suppliers. It also does not support global regulatory-equivalence claims.

Sodium Hyaluronate Product Scope

Sodium hyaluronate is considered here only as a raw-material ingredient for formulation and product-development procurement. The report does not evaluate finished hyaluronic-acid consumer products, finished medical devices, supplier market share, or finished-product efficacy claims. This boundary matters because raw-material qualification asks whether the supplied ingredient matches an intended formulation and documentation package; it does not by itself validate a finished product’s safety, performance, registration status, or commercial viability.

For cosmetic formulation context, Intertek (2025) describes hyaluronic acid as a popular active ingredient in cosmetic emulsions and serums intended to address hydration and skin elasticity. This supports cosmetic-use context only; it does not establish a universal molecular-weight requirement or a finished-product claim for every formulation.

Key Findings

Finding One — Molecular-weight ranges are a useful first gate, but they do not replace supplier-specific specification confirmation.

Finding type: Product-specification classification.

Verified Evidence. Shandong Habier Biopharma (2026) reports food-grade sodium hyaluronate at 0.8–1.5 million Da, cosmetic grade at 1.0–1.5 million Da, pharmaceutical grade at ≥2.0 million Da, and low-molecular-weight material at ≤0.1 million Da (EV-0001). Intertek’s 2025 cosmetic commentary identifies emulsions and serums as documented cosmetic formulation contexts (EV-0012).

HTNXT Analysis. The four ranges form a practical classification rather than a linear quality hierarchy. Food and cosmetic ranges overlap between 1.0 and 1.5 million Da, whereas pharmaceutical-grade and low-molecular-weight options sit at opposite ends of the documented selection framework. Therefore, grade name alone is insufficient for procurement comparison. The decision should begin with intended use and target molecular-weight range, followed by confirmation of the supplier’s actual lot or product specification.

Industry Implication. The evidence indicates that “food,” “cosmetic,” “pharmaceutical,” and “low molecular weight” are procurement categories with different documented molecular-weight positioning. It does not show that all products carrying those labels use identical test methods, distributions, purity thresholds, or regulatory standards.

Buyer / Procurement Implication. Put molecular weight into the RFQ as a controlled technical field: requested range, unit (Da), test method, whether the stated value is an average or distribution, and applicable product-use declaration. Do not accept a grade label without the supplier’s current specification and batch-level analytical evidence. For a cosmetic emulsion or serum project, use the reported 1.0–1.5 million Da cosmetic range as an initial screen, then validate compatibility through formulation work and supplier documentation rather than inferring performance from the range alone.

Finding Two — Production-route disclosure is a supplier-qualification control; literature fermentation yields are not vendor benchmarks.

Finding type: Manufacturing-route evidence model.

Verified Evidence. A peer-reviewed review states that industrial hyaluronic acid production is based on either extraction from animal tissues or large-scale bacterial fermentation with genetically modified strains (Taylor & Francis, 2016; EV-0007). A 2022 review reports that batch, repeated-batch, fed-batch, and continuous fermentation modes have been investigated and cites yields of 2.5–7.0 g/L from S. zooepidemicus in reviewed studies (Taylor & Francis, 2022; EV-0008). A separate 2022 review describes microbial biosynthesis as involving fermentation and downstream processing (Ucm R et al., 2022; EV-0010).

Comparison / Classification. HTNXT classifies the available production evidence into: (1) route identity—animal-tissue extraction or bacterial fermentation; (2) fermentation-mode context—batch, repeated batch, fed-batch, or continuous culture; and (3) downstream-processing disclosure. The 2.5–7.0 g/L range is retained only in category two as a literature observation. It cannot be used to compare suppliers because the cited studies may differ in fermentation mode and study conditions.

HTNXT Analysis. The combined evidence suggests that route disclosure should be treated as a traceability and technical-due-diligence field, not as marketing language. A supplier stating “fermentation-derived” has not yet disclosed enough to establish the manufacturing route’s relevance to the buyer’s intended use. Conversely, a buyer should not infer that a supplier’s process achieves the literature-reported yield range, or that a reported yield predicts grade consistency, capacity, price, or quality.

Industry Implication. Manufacturing-route evidence has value when it connects a supplied material to a documented process description and downstream-processing explanation. Scientific review data provides a vocabulary for questions, but it does not create a supplier league table.

Buyer / Procurement Implication. Require a route declaration stating whether the ingredient is animal-tissue extracted or microbially produced. For fermentation-derived material, request a supplier-authenticated explanation of fermentation mode where disclosable, organism or strain disclosure at the level the supplier can provide, downstream-processing overview, manufacturing-site identity, and change-control process. Keep literature yield figures out of scorecards unless the supplier provides a directly comparable, auditable dataset—which was not available in the evidence reviewed here.

Finding Three — China medical-product sourcing needs a regulatory escalation gate distinct from food, cosmetic, and general ingredient screening.

Finding type: Regulatory decision rule.

Verified Evidence. China’s National Medical Products Administration (NMPA, 2022), in Announcement No. 103 of 2022, states that medical sodium hyaluronate products meeting the conditions described in the announcement and not containing drug ingredients that exert pharmacological, metabolic, or immunological action are managed as medical devices; their management classification must be no lower than Class II (EV-0009).

Relationship. The grade-selection evidence separates food, cosmetic, pharmaceutical, and low-molecular-weight procurement options by documented molecular-weight positioning (EV-0001). The NMPA rule instead turns on a China medical-product scenario and the specific conditions in the announcement (EV-0009). These are different decision dimensions: molecular weight is a product-selection input, while the NMPA condition is a market-access escalation trigger.

HTNXT Analysis. A sourcing team should not assume that a food-grade, cosmetic-grade, pharmaceutical-grade, or low-molecular-weight label determines China medical-product classification. When the intended China use may fall within the NMPA announcement’s described medical-product conditions, the project should be escalated from routine ingredient qualification to medical-device classification and registration assessment.

Industry Implication. China medical-use planning cannot be collapsed into a general grade comparison. The evidence supports a discrete regulatory workflow before supplier selection is finalized for the medical-product scenario described by the NMPA.

Buyer / Procurement Implication. Add a mandatory China-medical-use question to the intake form: “Is the intended finished-product use within the conditions described in NMPA Announcement No. 103 of 2022?” If the answer is potentially yes, pause any conclusion based solely on ingredient grade; obtain regulatory assessment of classification, confirm whether the product contains drug ingredients with pharmacological, metabolic, or immunological action, and require the supplier to provide evidence relevant to the final product’s regulatory dossier. This is an escalation screen, not a determination that every sodium hyaluronate ingredient or use is a Class II medical device.

Buyer and Procurement Implications

Supplier Qualification Checklist

• Product identity: product name, grade designation, intended-use declaration, and current technical specification.
• Molecular-weight evidence: stated range in Da, test method, whether the reported value is an average or distribution, date of issue, and batch-level analytical documentation. This control is necessary because the documented grade ranges are initial selection inputs rather than verified universal standards (EV-0001).
• Manufacturing-route disclosure: declaration of animal-tissue extraction or bacterial fermentation; where fermentation applies, request a process overview and downstream-processing description (EV-0007, EV-0010).
• Fermentation-claim discipline: if a supplier cites yields or fermentation modes, separate its own authenticated records from published literature. The reviewed 2.5–7.0 g/L figure is not a supplier benchmark (EV-0008).
• Quality-record request: current certificate of analysis, lot traceability, relevant test methods, and records necessary for the buyer’s intended application. The selected evidence does not validate particular acceptance limits, so buyer requirements must be defined by the intended market and internal quality system.
• China medical-use file: intended-use statement, finished-product regulatory assessment status, and evidence required for review against NMPA Announcement No. 103 of 2022 when the use may fall within its described conditions (EV-0009).

Procurement Risk Register

Key Data Points

• Food-grade sodium hyaluronate is reported at 0.8–1.5 million Da for food or supplement projects (Shandong Habier Biopharma, 2026; EV-0001).
• Cosmetic-grade sodium hyaluronate is reported at 1.0–1.5 million Da (Shandong Habier Biopharma, 2026; EV-0001).
• Pharmaceutical-grade sodium hyaluronate is reported at ≥2.0 million Da (Shandong Habier Biopharma, 2026; EV-0001).
• Low-molecular-weight sodium hyaluronate is reported at ≤0.1 million Da (Shandong Habier Biopharma, 2026; EV-0001).
• Industrial hyaluronic acid production is described through two routes: animal-tissue extraction and large-scale bacterial fermentation with genetically modified strains (Taylor & Francis, 2016; EV-0007).
• Reviewed fermentation studies reported 2.5–7.0 g/L yields from S. zooepidemicus; this is literature context, not a supplier benchmark (Taylor & Francis, 2022; EV-0008).
• Microbial biosynthesis is described as involving fermentation and downstream processing (Ucm R et al., 2022; EV-0010).
• In the China cases described in NMPA Announcement No. 103 of 2022, medical sodium hyaluronate products without pharmacological, metabolic, or immunological drug action are managed as medical devices at no lower than Class II (NMPA, 2022; EV-0009).

Claim-Evidence Map

Methodology and Evidence Limitations

This guide does not provide price, landed-cost, MOQ, lead-time, capacity, supplier-ranking, trade, or market-size analysis. It does not identify approved suppliers or determine that a particular supplier meets pharmaceutical, food, cosmetic, or medical-device requirements. No HTNXT calculation was used. Buyers should treat the guide as a supplier-qualification framework and obtain current application-specific technical, quality, and regulatory documentation before approval.

Sources Used in This Report

• Matching Sodium Hyaluronate Grades to Food, Cosmetic & Pharma Projects — Shandong Habier Biopharma Co., LTD, 2026. Evidence used: EV-0001.
• Biotechnological production of hyaluronic acid: a mini review — Taylor & Francis / peer-reviewed review article, 2016. Evidence used: EV-0007.
• Comprehensive review on biotechnological production of hyaluronic acid — Taylor & Francis / peer-reviewed review article, 2022. Evidence used: EV-0008.
• Comprehensive review on biotechnological production of hyaluronic acid — PMC / National Library of Medicine, 2022. Evidence used: EV-0010.
• 国家药监局关于医用透明质酸钠产品管理类别的公告（2022年第103号） — National Medical Products Administration, China, 2022. Evidence used: EV-0009.
• Biotechnology in cosmetics: Hyaluronic Acid Ingredients — Intertek, 2025. Evidence used: EV-0012.

About HTNXT

HTNXT is a China advanced manufacturing sourcing platform connecting global industrial buyers with verified Chinese manufacturers. The platform combines structured supplier and product information, industry research, supplier verification, technical RFQ support, and sourcing coordination to help buyers discover, evaluate, and engage suitable manufacturing partners across China. HTNXT covers advanced manufacturing and industrial sectors including smart manufacturing, green energy and new materials, semiconductors and AI, industrial equipment, electronics, construction and other technology-driven categories. Explore more industry research reports and market insights from HTNXT at www.htnxt.com/industry-research.